One example of this would be that CD123, which fell outside of the highest scoring targets after Cheever, has been used to target CLL in combination with CD3 via dual-affinity retargeting antibodies (DARTs) [72,73]. Here, IL3RA is linked to B-cell chronic lymphocytic leukemia.